{
  "pmcid": "12417316",
  "sha256": "8bf41d2c3be70d026738ed25a6002cd21fa97ffd856b3d01b4f432f4a00b8aee",
  "timestamp_utc": "2025-11-09T15:40:50.322748+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.886678571428572,
    "reading_ease": 22.099988095238132,
    "word_count": 224
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "retrospective cohort study"
      },
      "Participants": {
        "score": 2,
        "evidence": "487,676 patients with aECAD"
      },
      "Intervention": {
        "score": 2,
        "evidence": "CEA and CAS on AD and non‐AD dementia incidence"
      },
      "Objective": {
        "score": 1,
        "evidence": "evaluate the effect of CEA and CAS on AD and non‐AD dementia incidence"
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "37,317 patients underwent CEA or CAS"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "CEA was associated with a significantly lower AD risk (relative risk = 0.93; 95% confidence interval, 0.86–0.99; P < 0.05)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  }
}